Jody speaks with Josh Bartch, CEO and director of Mydecine Innovations Group (MYCO.NEO), a psychedelics company focused on advancing its lead psilocybin drug candidate MYCO-001 into Phase II clinical trials for use in smoking cessation therapies.
Latest News
“The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
